06 Apr CLLS Update
CLLS- $29 Recently we saw CLLS soar to $38 per share from $31 on news that Pfizer through a new private entity called Allogene Therapeutics was continuing the UCART 19 development program with Cellectis. The same day the stock soared CLLS announced a 5 million share...